Versantis Raises CHF 16m to Develop its Therapies for Liver Cirrhosis and Rare Disorders

What is Versantis' mission and core innovation?

 

We are committed to bring therapeutic solutions to many patients in need by timely supporting acute decompensations of liver cirrhosis (most advanced program) as well as rare urea cycle disorders in children.

 

How will the 16-million series-B investment from Swisscanto Invest, Esperante Ventures, and investiere help achieve your vision?
 

The Series B was oversubscribed, so we were able to raise more than we wanted. More importantly, with this new financing we will demonstrate the clinical proof of efficacy (Phase 2a) of VS-01 in 2 indications, which will open partnering and licensing opportunities. In addition, we have experienced, world class investors that have vast experience in guiding small biotech companies like Versantis through all aspects of corporate development and clinical development strategy.

 

Globally, 850 million people live with a liver disease and 2 million die every year. Modern lifestyle related liver diseases due to high calories diet and sedentarism are becoming the dominant drivers of decompensated cirrhosis and liver transplantations. At present, there are no drugs approved to support such cases, which are associated with high mortality if not medically managed early. By reversing the consequences of the liver decompensation, VS-01 aims to urgently fill this medical gap.

You won Venture Kick in 2015. How did this lay the foundation for your growth?
 

Venture Kick was the first believer in our team, technology, and vision. The whole Venturelab team provided huge support since the inception of the Versantis. Besides the funding, their critical guidance to successfully grow our startup into a mature biotech company was key. The access to Venture Kick’s local and national network was an excellent opportunity to continually challenge our strategy, help us to look ahead, and fortify our foundations in all aspects of corporate development and clinical development strategy.

 

Versantis also ranked at the TOP 100 Swiss Startup Award each of the past five years.  Did this distinction help your startup?

 

The event is a fantastic networking opportunity and a great visibility boost on the national stage. We are proud to be repeatedly voted among the two best Biotech companies.